VYNE Therapeutics reported FY 2025 royalty revenues of USD 0.6 million (+13.8%), with total operating expenses of USD 30.3 million (-31.3%), including R&D expense of USD 19.2 million (-37.8%) and G&A expense of USD 11.1 million (-16.0%). Operating loss was USD 29.7 million (-31.8%) and net loss was USD 26.5 million (-33.5%). Other income, net was USD 3.0 million (-21.3%). As of Dec. 31, 2025, VYNE had USD 29.0 million in cash, cash equivalents and marketable securities, no outstanding debt, and an accumulated deficit of USD 757.7 million; net cash used in operating activities in FY 2025 was USD 33.1 million. On the pipeline and corporate front, VYNE said it terminated its Phase 2b repibresib gel (VYN201) vitiligo trial after it did not meet the primary endpoint, and halted its Phase 1b VYN202 psoriasis study following an FDA clinical hold tied to non-clinical dog toxicology; the FDA later lifted the hold for two doses in female subjects while requiring additional dog toxicology to resume studies in male subjects, with a repeat study initiated in October 2025 and final report expected in Q4 2026. The company also highlighted a strategic review launched in August 2025 and the signing of a merger agreement with Yarrow Biosciences, targeting a close in Q2 2026, alongside a planned pre-closing special cash dividend expected to total about USD 14.5 million to USD 16.5 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001566044-26-000002), on February 27, 2026, and is solely responsible for the information contained therein.
Comments